UniSuper Management Pty Ltd Raises Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

UniSuper Management Pty Ltd lifted its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 20.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,033 shares of the medical research company’s stock after acquiring an additional 1,724 shares during the quarter. UniSuper Management Pty Ltd’s holdings in Charles River Laboratories International were worth $1,852,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Wellington Management Group LLP boosted its position in Charles River Laboratories International by 135,927.9% during the third quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock worth $736,819,000 after purchasing an additional 3,738,018 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Charles River Laboratories International during the 4th quarter worth $42,776,000. Cooke & Bieler LP boosted its position in shares of Charles River Laboratories International by 42.1% in the 4th quarter. Cooke & Bieler LP now owns 426,767 shares of the medical research company’s stock worth $78,781,000 after buying an additional 126,372 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in Charles River Laboratories International by 21.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock valued at $95,086,000 after acquiring an additional 85,759 shares in the last quarter. Finally, M.D. Sass LLC raised its position in Charles River Laboratories International by 22.0% during the fourth quarter. M.D. Sass LLC now owns 391,824 shares of the medical research company’s stock worth $72,331,000 after acquiring an additional 70,652 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Morgan Stanley lowered their price target on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 5th. UBS Group reissued a “neutral” rating and set a $185.00 price target (down previously from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. Barclays reduced their price objective on Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 18th. William Blair cut Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 22nd. Finally, JPMorgan Chase & Co. reduced their target price on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating on the stock in a report on Thursday, February 20th. One analyst has rated the stock with a sell rating and sixteen have given a hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $189.77.

Charles River Laboratories International Trading Down 1.6 %

CRL stock opened at $155.60 on Monday. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The company has a market cap of $7.96 billion, a price-to-earnings ratio of 1,037.35, a PEG ratio of 4.54 and a beta of 1.45. The business has a fifty day simple moving average of $164.69 and a 200-day simple moving average of $182.60. Charles River Laboratories International, Inc. has a 52 week low of $150.79 and a 52 week high of $273.32.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping the consensus estimate of $2.50 by $0.16. The company had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm’s revenue was down 1.1% on a year-over-year basis. During the same period in the prior year, the firm posted $2.46 earnings per share. On average, equities research analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, COO Birgit Girshick acquired 1,514 shares of the company’s stock in a transaction dated Thursday, February 20th. The stock was bought at an average price of $164.63 per share, with a total value of $249,249.82. Following the completion of the transaction, the chief operating officer now directly owns 55,058 shares of the company’s stock, valued at approximately $9,064,198.54. The trade was a 2.83 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Joseph W. Laplume sold 4,400 shares of Charles River Laboratories International stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total transaction of $715,000.00. Following the transaction, the executive vice president now owns 20,013 shares in the company, valued at $3,252,112.50. The trade was a 18.02 % decrease in their position. The disclosure for this sale can be found here. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).